Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.

Molecular cancer therapeutics - 1 Feb 2020

Nassar Amin H, Hamieh Lana, Gray Kathryn P, Thorner Aaron R, Fay Andre P, Lasseter Kathryn D, Abou Alaiwi Sarah, Nuzzo Pier Vitale, Flippot Ronan, Krajewski Katherine M, Signoretti Sabina, Choueiri Toni K, Kwiatkowski David J

Abstract excerpt

We previously showed that alterations in mTOR pathway genes were correlated with response to rapalog therapy in metastatic renal cell carcinoma (mRCC), when the analysis focused on extremes of response. Herein, we expand on the prior cohort and examine genetic correlations with rapalog response in a dataset not selected for extremes of response. Tumors from 58 patients from the phase III trial of temsirolimus and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Renal Cell

Share to PBRM1 gene

Share to Kidney Neoplasms

Share to Mutation

Share to Neoplasm Metastasis

Share to Survival Analysis

Source

Identifiers

PMID: 31653662
DOI: 10.1158/1535-7163.MCT-19-0642

Genes

TSC1
BAP1
KDM5C
MTOR
PBRM1
PIK3CA
PTEN
SETD2
TP53
TSC2
VHL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.PMID 31653662Read ↗

Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.Semantic proximity Read ↗

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.Semantic proximity Read ↗

PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinomaSemantic proximity Read ↗

Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor TherapySemantic proximity Read ↗

PTEN loss confers sensitivity to rapalogs in clear cell renal cell carcinoma.Semantic proximity Read ↗

Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.Semantic proximity Read ↗

Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.Semantic proximity Read ↗

Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.Semantic proximity Read ↗

Enhancing mTOR-targeted cancer therapySemantic proximity Read ↗

Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression.Semantic proximity Read ↗

A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.Semantic proximity Read ↗

Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.